Log In
Print
BCIQ
Print
Print this Print this
 

Baraclude, entecavir

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionCyclopentile guanosine nucleoside analog
Molecular Target Viral polymerase
Mechanism of ActionViral polymerase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat antiviral naive chronic HBV infection in HBeAg-positive patients; Treat chronic HBV infection; Treat chronic HBV infection in adult patients with evidence of decompensated liver disease; Treat chronic HBV infection in adults; Treat chronic HBV infection in nucleoside-naïve pediatric patients ages 2 to <18 years with compensated liver disease; Treat chronic HBV infection in nucleoside-naïve, HBeAg-negative patients; Treat chronic HBV infection in nucleoside-naïve, HBeAg-positive patients; Treat chronic HBV infection in nucleoside-naïve, lamivudine-resistant, HBeAg-negative patients; Treat chronic HBV infection in nucleoside-naïve, lamivudine-resistant, HBeAg-positive patients; Treat HBV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today